Prices are updated after-hours

NightHawk Biosciences Inc

NHWK | $0.4135 0.0% 170K

(0.0% 1d) (0.0% 1m) (-45.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 10,784,862
https://www.heatbio.com
Sec Filling | Patents | 39 employees

(US) Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

antibody vaccine infectious disease cancer t-cell covid hepatitis

add to watch list Paper trade email alert is off

Evaxion Biotech A/S - ADR

EVAX | $4.19 -2.78% -0.48% 9.9K

Manufacturing

(0.0% 1d) (35.2% 1m) (199.3% 1y) (0.0% 2d) (0.0% 3d) (2.7% 7d) (-68.03% volume)
Earnings Calendar:
Market Cap: $ 21,851,080
https://www.evaxion-biotech.com
Sec Filling | Patents | 2020 employees

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

vaccine cancer immunotherapy infectious disease injection batteries skin

add to watch list Paper trade email alert is off

ImmunityBio Inc

IBRX | $4.94 -6.26% -6.57% 3.9M

Manufacturing

(0.0% 1d) (-3.0% 1m) (116.2% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 3,344,396,850
https://immunitybio.com
Sec Filling | Patents | n/a employees

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

cancer t-cell infectious disease immunotherapy ceiling injection optical

add to watch list Paper trade email alert is off

Immunocore Holdings plc - ADR

IMCR | $55.82 0.25% 0.17% 300K

Manufacturing

(0.0% 1d) (-10.7% 1m) (-5.2% 1y) (0.0% 2d) (0.0% 3d) (2.3% 7d) (-33.92% volume)
Earnings Calendar:
Market Cap: $ 2,780,986,618
https://www.immunocore.com
Sec Filling | Patents | 2020 employees

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

urea cancer immunotherapy infectious disease

add to watch list Paper trade email alert is off